Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 6 studies | 24% ± 5% | |
glutamatergic neuron | 6 studies | 41% ± 22% | |
GABAergic neuron | 6 studies | 34% ± 18% | |
oligodendrocyte | 6 studies | 25% ± 6% | |
astrocyte | 5 studies | 27% ± 8% | |
oligodendrocyte precursor cell | 5 studies | 27% ± 9% | |
neuron | 4 studies | 25% ± 8% | |
epithelial cell | 4 studies | 37% ± 6% | |
interneuron | 4 studies | 40% ± 20% | |
B cell | 3 studies | 17% ± 3% | |
ciliated cell | 3 studies | 25% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 38% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 3135.49 | 2642 / 2642 | 100% | 30.15 | 705 / 705 |
esophagus | 100% | 2397.54 | 1445 / 1445 | 100% | 25.70 | 183 / 183 |
ovary | 100% | 3268.28 | 180 / 180 | 100% | 24.05 | 430 / 430 |
breast | 100% | 2756.51 | 459 / 459 | 100% | 25.77 | 1117 / 1118 |
prostate | 100% | 2337.36 | 245 / 245 | 100% | 18.97 | 501 / 502 |
uterus | 100% | 2622.16 | 170 / 170 | 100% | 26.06 | 458 / 459 |
lung | 100% | 2299.21 | 577 / 578 | 100% | 31.13 | 1154 / 1155 |
bladder | 100% | 2553.33 | 21 / 21 | 100% | 19.45 | 502 / 504 |
thymus | 100% | 2551.44 | 653 / 653 | 99% | 22.89 | 601 / 605 |
intestine | 100% | 2473.17 | 966 / 966 | 99% | 16.50 | 523 / 527 |
stomach | 100% | 2056.74 | 359 / 359 | 99% | 16.66 | 283 / 286 |
pancreas | 100% | 1334.78 | 327 / 328 | 99% | 15.90 | 176 / 178 |
kidney | 100% | 1721.79 | 89 / 89 | 98% | 14.59 | 884 / 901 |
skin | 100% | 2561.64 | 1809 / 1809 | 98% | 21.33 | 462 / 472 |
adrenal gland | 100% | 2337.02 | 258 / 258 | 98% | 16.67 | 225 / 230 |
liver | 100% | 1511.13 | 226 / 226 | 97% | 11.88 | 393 / 406 |
adipose | 100% | 2687.24 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2475.25 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 16.65 | 29 / 29 |
muscle | 100% | 2562.76 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2169.85 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 31.55 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.23 | 1 / 1 |
heart | 99% | 1669.08 | 849 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 9.99 | 72 / 80 |
peripheral blood | 83% | 1201.77 | 770 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016925 | Biological process | protein sumoylation |
GO_0051028 | Biological process | mRNA transport |
GO_0031648 | Biological process | protein destabilization |
GO_0016926 | Biological process | protein desumoylation |
GO_0006508 | Biological process | proteolysis |
GO_0015031 | Biological process | protein transport |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0030111 | Biological process | regulation of Wnt signaling pathway |
GO_0045444 | Biological process | fat cell differentiation |
GO_0031397 | Biological process | negative regulation of protein ubiquitination |
GO_0005643 | Cellular component | nuclear pore |
GO_0005634 | Cellular component | nucleus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0016605 | Cellular component | PML body |
GO_0031965 | Cellular component | nuclear membrane |
GO_0016929 | Molecular function | deSUMOylase activity |
GO_0070139 | Molecular function | SUMO-specific endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | SENP2 |
Protein name | SUMO specific peptidase 2 Sentrin-specific protease 2 (EC 3.4.22.-) (Axam2) (SMT3-specific isopeptidase 2) (Smt3ip2) (Sentrin/SUMO-specific protease SENP2) |
Synonyms | KIAA1331 |
Description | FUNCTION: Protease that catalyzes two essential functions in the SUMO pathway . The first is the hydrolysis of an alpha-linked peptide bond at the C-terminal end of the small ubiquitin-like modifier (SUMO) propeptides, SUMO1, SUMO2 and SUMO3 leading to the mature form of the proteins . The second is the deconjugation of SUMO1, SUMO2 and SUMO3 from targeted proteins, by cleaving an epsilon-linked peptide bond between the C-terminal glycine of the mature SUMO and the lysine epsilon-amino group of the target protein . May down-regulate CTNNB1 levels and thereby modulate the Wnt pathway (By similarity). Deconjugates SUMO2 from MTA1 . Plays a dynamic role in adipogenesis by desumoylating and promoting the stabilization of CEBPB . Acts as a regulator of the cGAS-STING pathway by catalyzing desumoylation of CGAS and STING1 during the late phase of viral infection (By similarity). . |
Accessions | F8WCX8 F8WED6 ENST00000296257.10 [Q9HC62-1] F8WET6 ENST00000430355.5 ENST00000453532.5 Q9HC62 F8WED7 C9IYB7 ENST00000444509.1 ENST00000413407.5 H7C1A0 ENST00000439684.5 ENST00000458551.1 |